New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
05:48 EDTINOInovio broadens IP portfolio from UPenn
Inovio Pharmaceuticals has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators. Inovio has an ongoing collaborative research agreement with the university to support fundamental research in the area of DNA-based vaccines and immunotherapies. All newly licensed products are in preclinical development. These new pipeline candidates were developed using Inovio's SynCon design approach and were constructed and tested in preclinical animal models for their ability to generate potent antigen-specific T cell and antibody responses. Multiple patents have been filed and several manuscripts are being prepared for peer-reviewed journal publications. Overall, this amendment broadens and strengthens the patent protection around previously licensed oncology and infectious disease targets by in-licensing expanded patents covering candidate products for DNA based synthetic antibodies and those covering dengue fever, H7N9 influenza, additional HPV serotypes as well as certain other undisclosed cancer antigen targets.
News For INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
06:10 EDTINOInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 15, 2014
11:27 EDTINOOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INO ATLS LOCO OPK INFY EUO FDO

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use